(Q39941183)

English

Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren

scientific article published on 10 September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Sujata Vaidyanathan

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Gian Camenisch

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Helmut Schuetz

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Christine Reynolds

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Ching-Ming Yeh

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Marie-Noelle Bizot

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Hans Armin Dieterich

7

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Dan Howard

8

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

William P Dole

9

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

publication date

10 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

48

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1323-1338

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Transporters and drug therapy: implications for drug disposition and disease

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Role of transport proteins in drug absorption, distribution and excretion

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

The renin-angiotensin-aldosterone system: a specific target for hypertension management

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Structure-based design of aliskiren, a novel orally effective renin inhibitor

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of aliskiren

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Renin inhibition with aliskiren: where are we now, and where are we going?

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Current industrial practices of assessing permeability and P-glycoprotein interaction

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Influence of passive permeability on apparent P-glycoprotein kinetics.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Digoxin remains useful in the management of chronic heart failure

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Blood concentrations of everolimus are markedly increased by ketoconazole

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Clinical Pharmacokinetics of Atorvastatin

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

HEK293 cell line: a vehicle for the expression of recombinant proteins

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Effects of cardiovascular drugs on ATPase activity of P-glycoprotein in plasma membranes and in purified reconstituted form

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323258

21 January 2018

Identifiers

10.1177/0091270008323258

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39941183&oldid=1879136526"